Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Boceprevir or telaprevir in hepatitis C virus chronic infection: The Italian real life experience.
Cleo Study Group, Ascione A, Adinolfi LE, Amoroso P, Andriulli A, Armignacco O, Ascione T, Babudieri S, Barbarini G, Brogna M, Cesario F, Citro V, Claar E, Cozzolongo R, D'Adamo G, D'Amico E, Dattolo P, De Luca M, De Maria V, De Siena M, De Vita G, Di Giacomo A, De Marco R, De Stefano G, De Stefano G, Di Salvo S, Di Sarno R, Farella N, Felicioni L, Fimiani B, Fontanella L, Foti G, Furlan C, Giancotti F, Giolitto G, Gravina T, Guerrera B, Gulminetti R, Iacobellis A, Imparato M, Iodice A, Iovinella V, Izzi A, Liberti A, Leo P, Lettieri G, Luppino I, Marrone A, Mazzoni E, Messina V, Monarca R, Narciso V, Nosotti L, Pellicelli AM, Perrella A, Piai G, Picardi A, Pierri P, Pietromatera G, Resta F, Rinaldi L, Romano M, Rossini A, Russello M, Russo G, Sacco R, Sangiovanni V, Schiano A, Sciambra A, Scifo G, Simeone F, Sullo A, Tarquini P, Tundo P, Vallone A. Cleo Study Group, et al. Among authors: tarquini p. World J Hepatol. 2016 Aug 8;8(22):949-56. doi: 10.4254/wjh.v8.i22.949. World J Hepatol. 2016. PMID: 27574549 Free PMC article.
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study.
Petta S, Marzioni M, Russo P, Aghemo A, Alberti A, Ascione A, Antinori A, Bruno R, Bruno S, Chirianni A, Gaeta GB, Giannini EG, Merli M, Messina V, Montilla S, Perno CF, Puoti M, Raimondo G, Rendina M, Silberstein FC, Villa E, Zignego AL, Pani L, Craxì A; ABACUS study group; AIFA team. Petta S, et al. Lancet Gastroenterol Hepatol. 2017 Jun;2(6):427-434. doi: 10.1016/S2468-1253(17)30048-1. Epub 2017 Apr 10. Lancet Gastroenterol Hepatol. 2017. PMID: 28497758
High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients.
Pellicelli A, Messina V, Giannelli V, Distefano M, Palitti VP, Vignally P, Tarquini P, Izzi A, Moretti A, Babudieri S, Dell'Isola S, Marignani M, Scifo G, Iovinella V, Cariti G, Pompili M, Candilo FD, Fontanella L, Ettorre GM, Vennarecci G, Ippolito AM, Barbarini G. Pellicelli A, et al. Among authors: tarquini p. Gut Liver. 2020 May 15;14(3):357-367. doi: 10.5009/gnl18269. Gut Liver. 2020. PMID: 30970444 Free PMC article.
Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study.
Pellicelli AM, Pace Palitti V, Vignally P, Ceccherini-Silberstein F, Siciliano M, Giannelli V, Moretti A, Tarquini P, Scifo G, Messina V, Ascione A, Izzi A, Marignani M, D'Ambrosio C, Fondacaro L, Ettorre GM, Ialongo P, Sacco R, Perno CF, Barbarini G; CLEO Group. Pellicelli AM, et al. Among authors: tarquini p. Liver Int. 2017 May;37(5):653-661. doi: 10.1111/liv.13288. Epub 2016 Dec 15. Liver Int. 2017. PMID: 27782373
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis.
Ascione A, De Luca M, Melazzini M, Montilla S, Trotta MP, Petta S, Puoti M, Sangiovanni V, Messina V, Bruno S, Izzi A, Villa E, Aghemo A, Zignego AL, Orlandini A, Fontanella L, Gasbarrini A, Marzioni M, Giannini EG, Craxì A; ABACUS Study Group. Ascione A, et al. Infection. 2018 Oct;46(5):607-615. doi: 10.1007/s15010-018-1157-x. Epub 2018 May 28. Infection. 2018. PMID: 29808463
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies.
Di Maio VC, Cento V, Lenci I, Aragri M, Rossi P, Barbaliscia S, Melis M, Verucchi G, Magni CF, Teti E, Bertoli A, Antonucci F, Bellocchi MC, Micheli V, Masetti C, Landonio S, Francioso S, Santopaolo F, Pellicelli AM, Calvaruso V, Gianserra L, Siciliano M, Romagnoli D, Cozzolongo R, Grieco A, Vecchiet J, Morisco F, Merli M, Brancaccio G, Di Biagio A, Loggi E, Mastroianni CM, Pace Palitti V, Tarquini P, Puoti M, Taliani G, Sarmati L, Picciotto A, Vullo V, Caporaso N, Paoloni M, Pasquazzi C, Rizzardini G, Parruti G, Craxì A, Babudieri S, Andreoni M, Angelico M, Perno CF, Ceccherini-Silberstein F; HCV Italian Resistance Network Study Group. Di Maio VC, et al. Among authors: tarquini p. Liver Int. 2017 Apr;37(4):514-528. doi: 10.1111/liv.13327. Epub 2017 Jan 20. Liver Int. 2017. PMID: 28105744
Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy.
Bertoli A, Sorbo MC, Aragri M, Lenci I, Teti E, Polilli E, Di Maio VC, Gianserra L, Biliotti E, Masetti C, Magni CF, Babudieri S, Nicolini LA, Milana M, Cacciatore P, Sarmati L, Pellicelli A, Paolucci S, Craxì A, Morisco F, Palitti VP, Siciliano M, Coppola N, Iapadre N, Puoti M, Rizzardini G, Taliani G, Pasquazzi C, Andreoni M, Parruti G, Angelico M, Perno CF, Cento V, Ceccherini-Silberstein F; HCV Virology Italian Resistance Network (VIRONET-C). Bertoli A, et al. Sci Rep. 2018 Jun 12;8(1):8988. doi: 10.1038/s41598-018-26862-y. Sci Rep. 2018. PMID: 29895871 Free PMC article. Clinical Trial.
Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
Angelico M, Koehler-Horst B, Piccolo P, Angelico F, Gentile S, Francioso S, Tarquini P, Vecchia RD, Ponti L, Pilleri G, Barlattani A, Grieco A, Soccorsi F, Guarascio P, Demelia L, Sorbello O, Rossi Z, Forlini G, Zaru S, Bandiera F; SMIEC II Investigators. Angelico M, et al. Among authors: tarquini p. Eur J Gastroenterol Hepatol. 2008 Jul;20(7):680-7. doi: 10.1097/MEG.0b013e3282f5196c. Eur J Gastroenterol Hepatol. 2008. PMID: 18679072 Clinical Trial.
HepaDisk - A new quality of life questionnaire for HCV patients.
Fagiuoli S, Caporaso N, Morisco F, Buelli F, Gualberti G, Saragaglia V, Chessa L, Corti G, Maida I, Mastroianni CM, Pirisi M, Russo FP, Farina F, Giannitrapani L, Toniutto P, Tarquini P, Tundo P, Vecchiet J, Vinci M, Taliani G; HepaDisk Study Group. Fagiuoli S, et al. Among authors: tarquini p. Dig Liver Dis. 2019 Jul;51(7):1008-1015. doi: 10.1016/j.dld.2018.12.009. Epub 2018 Dec 23. Dig Liver Dis. 2019. PMID: 30661988 Free article.
Comparison of a rule-based algorithm with a phenotype-based algorithm for the interpretation of HIV genotypes in guiding salvage regimens in HIV-infected patients by a randomized clinical trial: the mutations and salvage study.
Gianotti N, Mondino V, Rossi MC, Chiesa E, Mezzaroma I, Ladisa N, Guaraldi G, Torti C, Tarquini P, Castelli P, Di Carlo A, Boeri E, Keulen W, Kenna PM, Lazzarin A; Mutations and Salvage (MuSa) Study Group. Gianotti N, et al. Among authors: tarquini p. Clin Infect Dis. 2006 May 15;42(10):1470-80. doi: 10.1086/503568. Epub 2006 Apr 13. Clin Infect Dis. 2006. PMID: 16619162 Clinical Trial.
22 results